FDA / CDRH
United States — FDA / CDRH
FDA Premarket Cybersecurity Guidance & FD&C §524B
Authority
U.S. Food and Drug Administration, Center for Devices and Radiological Health
Enforced
Mar 2023
Legal framework
FD&C Act §524B + Feb 3 2026 Final Guidance, aligned to QMSR (21 CFR Part 820 / ISO 13485:2016, effective Feb 2 2026). Supersedes Jun 2025 guidance and replaces 2014 premarket cybersecurity guidance.
Scope
All cyber devices: software in or as a device, with internet connectivity, that could be vulnerable to cybersecurity threats. Applies to 510(k), De Novo, PMA, HDE and BLA submissions.
Pre-market
Cybersecurity treated as part of device safety under the QMSR (ISO 13485:2016). Secure Product Development Framework (SPDF) presented as one way to satisfy QMSR. Threat model, SBOM in machine-readable format, security risk management (AAMI TIR57), security architecture views (global system, multi-patient harm, updateability), security testing.
Post-market
Coordinated vulnerability disclosure plan, post-market monitoring, patching commitments and timelines for the supported device lifetime.
SBOM
Required§524B(b)(3): machine-readable SBOM (SPDX or CycloneDX) with known vulnerabilities and support level for each component.
Vulnerability disclosure
Mandatory CVD plan submitted with application. Updates must be free of charge.
Penalty
Refusal to Accept (RTA) of submission, adds months to clearance.
Unique requirements
- 01Section 524B is statutory, failure = RTA
- 02Architecture views (global system view, multi-patient harm view, updateability view)
- 03Free patches for the device lifetime
- 04Cybersecurity controls must be evidenced through the QMSR / ISO 13485 design controls, not just the submission
Highlights
- Cybersecurity = device safety under QMSR (ISO 13485:2016)
- SPDF positioned as one way to satisfy the QMSR
- SBOM in machine-readable format
- Lifecycle security plan with patch SLAs
Aligns with
Timeline
-
Dec 2022
Omnibus Act adds §524B to FD&C
-
Mar 29 2023
RTA enforcement begins
-
Sep 27 2023
Final cybersecurity guidance published
-
Jun 27 2025
Final guidance updated (supersedes 2023)
-
Feb 2 2026
QMSR (21 CFR Part 820 / ISO 13485:2016) takes effect
-
Feb 3 2026
Final guidance reissued aligned to QMSR; replaces 2014 premarket cybersecurity guidance and supersedes Jun 2025 version
Key documents
Final Guidance (Feb 3 2026): Cybersecurity in Medical Devices — Quality Management System Considerations and Content of Premarket Submissions
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket
Final Guidance PDF (Feb 3 2026)
https://www.fda.gov/media/119933/download
Quality Management System Regulation (21 CFR Part 820, effective Feb 2 2026)
https://www.federalregister.gov/documents/2024/02/02/2024-01709/medical-devices-quality-system-regulation-amendments
FDA Cybersecurity Hub (Digital Health CoE)
https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity
Cybersecurity in Medical Devices: FAQs
https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs
Postmarket Management of Cybersecurity in Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices
FDA 524B head-to-head
Related markets
Frequently asked about United States
Is SBOM required for medical devices in United States?
Required. §524B(b)(3): machine-readable SBOM (SPDX or CycloneDX) with known vulnerabilities and support level for each component.
What does FDA / CDRH require for pre-market cybersecurity?
Cybersecurity treated as part of device safety under the QMSR (ISO 13485:2016). Secure Product Development Framework (SPDF) presented as one way to satisfy QMSR. Threat model, SBOM in machine-readable format, security risk management (AAMI TIR57), security architecture views (global system, multi-patient harm, updateability), security testing.
What are the post-market cybersecurity obligations under FDA / CDRH?
Coordinated vulnerability disclosure plan, post-market monitoring, patching commitments and timelines for the supported device lifetime.
What is the penalty for non-compliance with FDA / CDRH cybersecurity rules?
Refusal to Accept (RTA) of submission, adds months to clearance.
How much of my FDA cybersecurity package is reusable in United States?
Roughly 100% — an editorial estimate based on overlapping evidence requirements (threat model, SBOM, security risk assessment, pen-test report).